Investment Rating - The industry investment rating is "Positive (Maintain)" [1] Core Insights - The report highlights the robust growth in the travel industry driven by the implementation of spring and autumn holiday policies, which are reshaping peak and off-peak travel patterns [14][18] - The AI infrastructure sector is experiencing significant opportunities due to the government's push for "computing and electricity collaboration," which is expected to enhance the efficiency of energy use in AI applications [39][40] - The dental industry, particularly the invisible orthodontics segment, is undergoing a transformation with the adoption of 3D printing technology, which is expected to improve user experience and operational efficiency [51][56] Summary by Sections Travel Industry - The spring holiday policy has been implemented in seven provinces, creating a six-day holiday that aligns with family travel needs, leading to increased flight bookings and stable ticket prices [14][18] - Tongcheng Travel reported a revenue of 4.84 billion yuan in Q4 2025, a year-on-year increase of 14.2%, with adjusted net profit reaching 780 million yuan, up 18.1% [21][23] - The core OTA business saw a revenue increase of 17.5%, driven by higher hotel bookings and improved operational efficiency [24][29] AI Infrastructure - The AI industry is entering a phase of rapid growth in data supply and application scenarios, with daily Token usage surpassing 140 trillion in March 2026, reflecting a 40% increase from the end of 2025 [39][41] - The government has included "computing and electricity collaboration" in its new infrastructure initiatives, emphasizing the importance of integrating energy and computing resources [40][39] - China's electricity costs are significantly lower than those in Europe and the US, providing a competitive advantage for AI model operations [44][46] Dental Industry - Angelalign, a leading player in the invisible orthodontics market, has seen its overseas business grow rapidly, with a revenue increase of 102.5% year-on-year in 2025 [51][58] - The company is leveraging 3D printing technology to streamline production processes, enhancing the customization of dental products [51][56] - The overall market for invisible orthodontics is expected to benefit from technological advancements and increased consumer demand, with projected revenues of 370 million USD in 2025 [51][55]

Group 1: New Companies Listed - Five new companies were listed this week, with an average revenue of 640 million yuan and a median of 719 million yuan for 2024, and an average net profit of 57.3 million yuan with a median of 43.9 million yuan [3][14] - The companies include Panguiao, a "small giant" in automotive parts and precision molds, and Helifang, a "small giant" in air source heat pumps [3][13] - Panguiao's main products include power system components, interior and exterior functional parts, and precision molds, serving major global automotive brands [15][17] - Helifang specializes in air source heat pumps, with products exported to multiple countries and a projected market share increase from 5.74% in 2023 to 8.21% in 2024 [4][39] Group 2: Market Dynamics - The total number of companies listed on the New Third Board is 5,933, with 2,257 in the innovation layer and 3,676 in the basic layer [5] - The total market value of listed companies reached 25,856.35 billion yuan, with a month-on-month increase of 13.17 billion yuan [5][4] - The trading volume for the week included significant transactions, with Zhongxin Jingyuan and Xinda Materials leading in trading amounts [5][12] Group 3: Industry Trends - The air source heat pump market is projected to grow significantly, with the European market expected to reach 14.2 billion USD in 2024 and 16.8 billion USD in 2025, with a compound annual growth rate of 19.3% from 2025 to 2034 [4][38] - The global heat pump market is anticipated to see an increase in installation capacity, with projections of over 3,000 GWth by 2035 under the STEPS scenario [38] - The demand for energy-efficient heating solutions is rising, driven by global energy transition policies and the push for carbon neutrality [25][31]

Report Industry Investment Rating - Not provided in the report Core Viewpoints - In the first two months of 2026, the cumulative year-on-year growth of revenues and profits of industrial enterprises was high. The year-on-year growth of profits of industrial enterprises above designated size was 15.2%, and the year-on-year growth of revenues was 5.3%. The growth of profits was better than that of revenues, possibly due to the reduced cost - side pressure at the beginning of the year [4][5]. - The profit structure of industrial enterprises continued to be differentiated. The proportion of equipment manufacturing increased by 2.1 percentage points year - on - year, while that of consumer goods manufacturing decreased by 6.2 percentage points year - on - year [5]. - From the aspects of volume, price, and profit margin, the increase in volume, the recovery of price, and the turn from negative to positive of profit margin promoted the significant year - on - year increase of the cumulative profits of industrial enterprises above designated size [6]. - There were structural highlights in industrial enterprise profit data. The new and old kinetic energy continued to transform, and the "ballast stone" role of the equipment manufacturing industry was obvious. The profit of the high - tech manufacturing industry increased significantly [7]. - The bond market yield continued to be differentiated, and the long - term yield fluctuated within a range. It was expected that the target range of the 10 - year Treasury bond was 2 - 3%, with a central value of 2.5% [7]. Summary by Relevant Catalogs 1 - 2 Month Industrial Enterprise Profit Concerns - In the first two months of 2026, the cumulative year - on - year growth of revenues and profits of industrial enterprises was high, laying a good foundation for the start of the 14th Five - Year Plan. The profit growth was better than the revenue performance, and the cost per 100 yuan of revenue decreased by 0.48 yuan compared with the previous value [5]. - The profit structure of industrial enterprises continued to be differentiated. The profit of some industries such as tobacco, textiles, furniture manufacturing, and wood processing decreased year - on - year, while that of railway ships, electrical machinery, and computer equipment increased year - on - year. The economy still faced structural adjustment pressure [5]. Breakdown of Industrial Enterprise Profits - In the first two months, the added value of industrial enterprises above designated size increased by 6.3% year - on - year, the PPI of all industrial products decreased by 1.2% year - on - year with a narrowing decline, and the revenue profit margin of industrial enterprises above designated size increased by 8.61 percentage points year - on - year, turning from negative to positive [6]. Structural Highlights in Industrial Enterprise Profit Data - The new and old kinetic energy continued to transform, and the equipment manufacturing industry played an obvious "ballast stone" role. The revenue of the equipment manufacturing industry increased by 8.9% year - on - year, driving the profit to increase by 23.5% year - on - year, and its profit accounted for 30.4% [7]. - The profit growth rate of the high - tech manufacturing industry was remarkable. In the first two months, the profit of high - tech manufacturing enterprises above designated size increased by 58.7% year - on - year, accelerating by 45.4 percentage points compared with the whole year of 2025, and driving the profit growth of all industrial enterprises above designated size by 7.9 percentage points [7]. Bond Market Situation - On March 27, the differentiation of bond market yields continued, and the long - term bond repair was still restricted, with the overall yield fluctuating within a range. It was necessary to pay attention to the March PMI data and the data of Treasury bond trading in February announced by the central bank at the beginning of March [7]. Bond Market Views - It was expected that the target range of the 10 - year Treasury bond was 2 - 3%, with a central value of 2.5%. The reasons included the falsification of the under - expected economic recovery, possible wide - credit and wide - fiscal policies at the beginning of 2026, expected inflation recovery, possible tightening of funds, and the lagging nature of the real estate market [7].

Domestic Macro Policy - The Central Political Bureau emphasized the importance of a correct performance view, urging local party committees to fully implement the new development concept and focus on high-quality development[3] - The State Council outlined six key areas for 2026, including promoting a unified national market and accelerating the development of new-generation intelligent manufacturing[3] - The National Development and Reform Commission plans to identify around 100 significant application scenario projects to drive economic growth[4] Infrastructure and Industry - Policies are focused on new productivity development, including initiatives in computing power, hydrogen energy, and new energy vehicles[14] - The National Data Bureau aims for 80% of new computing power facilities to utilize green electricity[15] Monetary Policy - The central bank continues to implement a moderately loose monetary policy, maintaining liquidity and stability in financial markets[16] - The People's Bank of China plans to use various monetary policy tools to ensure ample liquidity and stabilize the RMB exchange rate[17] Fiscal Policy - The fiscal policy will prioritize investments in people's livelihoods, with plans to increase public service spending and support consumer demand through various measures[18] - A special fund of 250 billion yuan will be allocated to support consumer goods replacement programs[19] Real Estate Policy - Multiple cities are optimizing housing provident fund policies to support housing consumption, including increasing loan limits and adjusting down payment ratios[21] Financial Regulation - The draft of the Financial Law aims to enhance the financial regulatory framework and prevent systemic financial risks[23] Trade Relations - U.S. President Trump announced a visit to China on May 14-15, with ongoing trade negotiations between the U.S. and China[25] - China has initiated two trade barrier investigations in response to U.S. trade actions[25] Overseas Macro Policy - The Federal Reserve maintained its interest rate target range at 3.50%-3.75%, indicating a cautious approach to future rate cuts[29] - The geopolitical situation in the Middle East remains uncertain, with ongoing negotiations between the U.S. and Iran regarding energy facility attacks[30] Risk Warning - There is a divergence in domestic and foreign monetary policies, with concerns that the implementation of domestic policies may not meet expectations[34]

Investment Rating - The investment rating for the non-bank financial sector is "Positive" (maintained) [1] Core Insights - The report highlights that the overseas business of brokerage firms has become a bright spot, while the insurance sector's fourth-quarter performance was somewhat under pressure due to fluctuations in the stock and bond markets. The long-term logic for non-bank financial services remains positive, driven by deposit migration and a slow bull market, with both brokerage and insurance valuations at historically low levels, indicating potential for resilience and left-side opportunities [4][5][6] Summary by Sections Brokerage Firms - The average daily trading volume for stock funds was 2.67 trillion, a decrease of 3% month-on-month, while the cumulative average daily trading volume for 2026 was 3.17 billion, an increase of 84% year-on-year. The total AUM for stock and mixed funds was 9.7 trillion, a slight increase of 0.1% month-on-month [5] - In 2025, 150 brokerage firms achieved operating income of 541.2 billion, a year-on-year increase of 20%, and net profit of 219.4 billion, a year-on-year increase of 31% [5] - The report recommends focusing on brokerage firms with low valuations and high contributions from wealth management profits, such as Huatai Securities and GF Securities, as well as leading firms like Guotai Junan and CITIC Securities [5] Insurance - The report notes that the net profit of five A-share listed insurance companies showed a slowdown in growth compared to the first three quarters, with the fourth-quarter net profit slightly below market expectations due to stock market declines and bond market fluctuations impacting investment income [6] - The report indicates that the migration of deposits has led to high growth in the liability side of insurance companies, while the asset side is experiencing short-term volatility due to geopolitical tensions [6] - Recommended stocks include China Pacific Insurance and China Life Insurance [6]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report highlights a significant performance disclosure period for listed companies, focusing on high-growth sectors such as gold and jewelry, cosmetics, and medical aesthetics, with a notable divergence in performance among consumer brands [4][25] - High-end domestic brands like Laopuhuangjin and Maogeping are showing strong growth, while brands that adapt to channel changes and possess differentiated product capabilities, such as Chaohongji and Shangmei, are also performing well [4][25] Summary by Sections Retail and Social Services Market Review - The retail and social services indices reported declines of 1.10% and 1.52% respectively during the week of March 23-27, 2026, ranking 19th and 24th among 31 primary industries [6][14] - The jewelry sector saw the highest weekly increase of 1.05%, while the hotel and restaurant sector led year-to-date performance with a 0.77% increase [18][20] Industry Dynamics - The report emphasizes the ongoing annual report disclosures from listed companies, with a focus on high-growth companies [25] - The gold and jewelry sector continues to show a trend towards high-end and fashionable products, with Laopuhuangjin and Chaohongji demonstrating exceptional performance [28][39] Investment Recommendations - Investment focus areas include: - Gold and jewelry brands with differentiated product capabilities, recommending Laopuhuangjin, Chaohongji, and Zhou Dafu [7][42] - Offline retail companies adapting to trends and AI-enabled cross-border e-commerce leaders, recommending Yonghui Supermarket and Jihong Co [7][39] - Cosmetics brands that meet emotional value and safety innovation, recommending Maogeping, Shangmei, and Beitaini [7][40] - Medical aesthetics firms with differentiated products and expanding chains, recommending Aimeike and Meilitiantian Medical Health [7][41] Company-Specific Insights - Laopuhuangjin reported a revenue of 27.303 billion yuan (+221.0%) and a net profit of 4.868 billion yuan (+230.5%) for FY2025, with expectations for continued growth in Q1 2026 [28][41] - Chaohongji achieved a revenue of 9.318 billion yuan (+43.0%) and a net profit of 497 million yuan (+156.7%) for FY2025, with rapid growth in its franchise business [45][46] - Maogeping's revenue reached 5.050 billion yuan (+30.0%) with a net profit of 1.205 billion yuan (+36.8%) for FY2025, showcasing strong performance in high-end channels [32][41] - Shangmei reported a revenue of 9.178 billion yuan (+35.1%) and a net profit of 1.103 billion yuan (+41.1%) for FY2025, with a focus on multi-category growth [32][41]

Investment Rating - The investment rating for the coal industry is "Positive" (maintained) [1] Core Viewpoints - The report indicates that coal prices are expected to rise, driven by high daily consumption and improved market sentiment. The price of thermal coal has slightly increased, with the Qinhuangdao Q5500 thermal coal closing at 761 RMB/ton, up 26 RMB/ton from the previous period. The report anticipates that prices will stabilize around the coal-electricity profit-sharing line of approximately 750 RMB/ton, with potential upward movement towards the 800-860 RMB range due to geopolitical tensions in the Middle East affecting oil prices and chemical products [3][4][5]. Summary by Sections Investment Logic - Thermal coal prices are at a turning point, expected to rise through a four-step process: repairing central and local long-term contracts, reaching the coal-electricity profit-sharing line, and potentially exceeding the breakeven point for power plants at 860 RMB. The report also notes that coking coal prices are influenced more by supply and demand fundamentals, with target prices based on the ratio of coking coal to thermal coal prices [4][15]. Investment Recommendations - The report outlines a dual logic for coal stocks: cyclical elasticity and stable dividends. It suggests that both thermal and coking coal prices are at historical lows, providing room for rebound. The report identifies four main lines for stock selection: 1. Cyclical logic: Jin控煤业, 兖矿能源 for thermal coal; 平煤股份, 淮北矿业, 潞安环能 for metallurgical coal 2. Dividend logic: 中国神华, 中煤能源, 陕西煤业 3. Diversified aluminum elasticity: 神火股份, 电投能源 4. Growth logic: 新集能源, 广汇能源 [5][16]. Key Market Indicators - As of March 27, 2026, the average PE ratio for the coal sector is 19.12, ranking it sixth from the bottom in the A-share market, while the PB ratio is 1.58, ranking eighth from the bottom. The coal index has slightly decreased by 1.21%, outperforming the CSI 300 index by 0.2 percentage points [29][34][35]. Thermal Coal Market - The report notes a slight increase in domestic thermal coal prices, with the Qinhuangdao Q5500 price at 761 RMB/ton, reflecting a 3.54% increase. Prices in various production areas have also risen, with notable increases in the Ordos and Shanxi regions [35][36]. Coking Coal Market - The price of coking coal at the Jing-Tang port has risen to 1750 RMB/ton, marking an 8.02% increase. The report highlights the sensitivity of coking coal prices to market conditions, with a significant rebound in futures prices [21][22]. Supply and Demand Dynamics - The report indicates that coal production rates have slightly increased, with the operating rate of coal mines in the Shanxi, Shaanxi, and Inner Mongolia regions at 84.2%. Additionally, daily consumption at coastal power plants has decreased, but inventory levels have also dropped, leading to an increase in available days of inventory [58][60].

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company reported a net profit attributable to shareholders of 40.37 billion, a year-on-year increase of 25.5%, with underwriting profit reaching 12.5 billion, up 119% year-on-year. Total investment income was 38.6 billion, reflecting a 12.8% increase year-on-year, with an investment return rate of 5.8%, up 0.1 percentage points year-on-year [5] - The company maintains a leading position in the industry, with a continuous decline in the combined ratio (COR). The implementation of unified pricing for non-auto insurance is expected to further improve the COR, solidifying its status as an industry leader [5] - The company plans to distribute a dividend of 0.68 HKD per share, a year-on-year increase of 26%, with a current dividend yield of 5.2%. The current stock price corresponds to a price-to-earnings (PE) ratio of 6.3/5.8/5.3 for 2026-2028 and a price-to-book (PB) ratio of 0.9/0.7/0.6 for the same period [5] Financial Performance Summary - The company achieved original insurance premium income of 555.8 billion, a year-on-year increase of 3.3%, with a market share of 31.6% in the Chinese property insurance market. The insurance service income was 511.6 billion, up 5.4% year-on-year [6] - The overall premium income growth was primarily driven by non-auto insurance, with the new energy vehicle insurance premium income reaching 67.1 billion, a year-on-year increase of 31.9%, accounting for 22.1% of total premiums [6] - The comprehensive cost ratio improved to 97.5%, down 1.3 percentage points year-on-year, while the comprehensive expense ratio decreased to 23.6%, down 2.2 percentage points year-on-year, indicating effective cost control [6] Investment Asset Growth - The company's total investment assets reached 760.4 billion, a year-on-year increase of 12.4%, with total investment income of 38.6 billion, up 12.8% year-on-year. The investment return rate remained at 5.8%, reflecting a slight year-on-year increase [7] - The proportion of equity investments increased to 27.9%, up 2.8 percentage points year-on-year, with stock assets accounting for 11.3%, an increase of 4.0 percentage points year-on-year [7] Valuation Metrics - The financial summary indicates projected insurance service income for 2026 at 540.75 billion, with a year-on-year growth of 5.7%. The net profit attributable to shareholders is expected to reach 45.97 billion in 2026, reflecting a year-on-year increase of 13.9% [8] - The projected comprehensive cost ratio for 2026 is 97.0%, with a payout ratio of 73.5%. The return on equity (ROE) is expected to be 15.0% [8]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Views - The report highlights a strong recovery in the biopharmaceutical sector, with significant growth in the "WuXi" companies, indicating a return to a prosperous cycle driven by increased demand and order expansion [4][34] - The report emphasizes the structural growth in the industry, particularly in preclinical services and small molecule CDMO, which are expected to accelerate in 2026 [5][36] Summary by Sections 1. "WuXi" Companies Performance - WuXi AppTec achieved a revenue of 45.46 billion RMB in 2025, a year-on-year increase of 15.8%, with a net profit of 19.15 billion RMB, reflecting a 102.7% increase [13] - WuXi Biologics reported a revenue of 21.79 billion RMB, up 16.7%, and a net profit increase of 45.3% [18] - WuXi STA's revenue grew by 46.7%, with a net profit increase of 69.9%, indicating strong order growth and demand recovery [26] 2. Growth Outlook for 2026 - WuXi AppTec expects a revenue growth of 18-22% for its continuing operations in 2026, with capital expenditures projected to rise to 6.5-7.5 billion RMB [4][35] - WuXi Biologics anticipates a revenue increase of 13-17% in 2026, factoring in currency fluctuations [34] - WuXi STA aims for a CAGR of 30-35% from 2025 to 2030, indicating robust growth potential [34] 3. Structural Growth Trends - The preclinical CRO sector is showing signs of recovery, with WuXi AppTec's testing services returning to positive growth and significant order increases in preclinical services [5][34] - Small molecule CDMO is expected to accelerate growth in 2026, driven by increased demand for GLP-1 class drugs [36] - ADC/XDC/TIDES CDMO sectors are maintaining high growth rates, with WuXi STA projecting a 25% CAGR over the next five years [38] 4. Market Performance - The biopharmaceutical sector rose by 1.56% in March 2026, outperforming the CSI 300 index by 2.97 percentage points [39] - The medical R&D outsourcing sector saw the largest gains, while the blood products sector experienced the most significant decline [40]

Group 1 - The IVD market in China is rapidly growing, with a market size of 118.5 billion yuan in 2023, driven by increasing clinical diagnostic demand and technological advancements, achieving a CAGR of 15.58% from 2016 to 2023 [1][24][23] - The global traditional IVD market was valued at 97 billion USD in 2022 and is expected to reach 121.8 billion USD by 2026, supported by technological innovations and the demand for early diagnosis and screening [1][27][24] - The IVD industry is segmented into various diagnostic methods, including immunodiagnostics, biochemical diagnostics, molecular diagnostics, and POCT, with immunodiagnostics being the most widely used due to its high sensitivity and accuracy [1][18][24] Group 2 - The North Exchange has four listed companies related to the gene medical and IVD industry chain: Danna Biological, Norseland, Sanyuan Gene, and Kangle Health [1][32] - There are 11 companies in the New Third Board related to the gene technology industry chain, including Baiying Biological, Bell Biological, and Kanghua Co., among others [1][35] - The North Exchange's medical and biological sector experienced a weekly decline of 2.83%, the smallest among five major industries, with 17.39% of medical and biological stocks rising [2][39][44] Group 3 - The report highlights the importance of IVD in clinical decision-making, as it provides critical diagnostic information throughout the disease treatment process, from initial diagnosis to monitoring and prognosis [1][15] - The IVD industry is characterized by a supply-side innovation driven by the discovery of new biomarkers, advancements in diagnostic technologies, and a growing demand for early diagnosis and precision medicine [1][27][24] - The report notes that the domestic IVD market is expected to continue its rapid growth due to factors such as population aging, increased healthcare spending, and the rising demand for accurate and early clinical diagnostic information [1][23][24]